Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Zhigang Fu, Xiaowei Li, Jiaming Zhong, et al.
Hepatology International (2021) Vol. 15, Iss. 3, pp. 663-675
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
Zhenwei Peng, Wenzhe Fan, Bowen Zhu, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 117-127
Closed Access | Times Cited: 286
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 187
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
Mingyue Cai, Wensou Huang, Jingjun Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 128
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 86
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 78
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
Deniz Tümen, Philipp Heumann, Karsten Gülow, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3202-3202
Open Access | Times Cited: 78
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jie-Yi Shi, Jian Zhou, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 2, pp. 206-216
Open Access | Times Cited: 71
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 64
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 41
Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
Song Chen, Zhiqiang Wu, Feng Shi, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 148, Iss. 8, pp. 2115-2125
Open Access | Times Cited: 89
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1788-1788
Open Access | Times Cited: 57
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
Wei‐Feng Qu, Zhen–Bin Ding, Xu-Dong Qu, et al.
BJS Open (2022) Vol. 6, Iss. 5
Open Access | Times Cited: 40
Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
Shuping Qu, Xiaobing Zhang, Yutian Wu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 38
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 32
Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
Xinhua Zou, Qingyu Xu, Ran You, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11315-11333
Open Access | Times Cited: 22
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
Mingyue Cai, Wensou Huang, Wei Liang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 920-930
Closed Access | Times Cited: 9
Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Lixing Li, Xin Xu, Wentao Wang, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010035-e010035
Open Access | Times Cited: 1
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Han Li, Zhenying Wu, Jiali Chen, et al.
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 5, pp. 1537-1549
Open Access | Times Cited: 34
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 383-396
Open Access | Times Cited: 33
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
Yan‐Jun Xiang, Kang Wang, Hongming Yu, et al.
Hepatology Research (2022) Vol. 52, Iss. 8, pp. 721-729
Closed Access | Times Cited: 33
Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
Ruihua Duan, Fen Gong, Yan Wang, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
Jun Ma, Zhiyuan Bo, Zhengxiao Zhao, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 625-625
Open Access | Times Cited: 17
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
Yanyu Wang, Xu Yang, Yun-Chao Wang, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 10, pp. 1614-1626
Open Access | Times Cited: 17
Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
Weijun Wang, Zong‐Han Liu, Kang Wang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11513-11524
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top